Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

Life sciences hubs beyond Boston and the Bay Area are giving startups new opportunities to grow and scale their businesses, ...

Regulatory submissions are entering a period of meaningful structural change. eCTD 4.0 is gaining traction at both the FDA and EMA, offering practical improvements over its predecessor: more flexible ...

Predicting how cells behave in a bioreactor is one of the more demanding challenges in biologics manufacturing. Classical data-driven models offer a practical starting point, but they rely on fitting ...

SK pharmteco’s ADC payload and linker solutions integrate scale, safety, and deep scientific expertise to support even the most technically demanding programs. Our right-sized, purpose-built ...

A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...